Skip to main content
Journal cover image

Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.

Publication ,  Journal Article
Antoszyk, AN; Tarnowski, KW; Basu, K; Ehrlich, JS; Haskova, Z
Published in: Ophthalmology. Retina
October 2020

Published In

Ophthalmology. Retina

DOI

EISSN

2468-6530

ISSN

2468-7219

Publication Date

October 2020

Volume

4

Issue

10

Start / End Page

1034 / 1036

Related Subject Headings

  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Tomography, Optical Coherence
  • Ranibizumab
  • Macular Edema
  • Intravitreal Injections
  • Humans
  • Diabetic Retinopathy
  • Angiogenesis Inhibitors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Antoszyk, A. N., Tarnowski, K. W., Basu, K., Ehrlich, J. S., & Haskova, Z. (2020). Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema. Ophthalmology. Retina, 4(10), 1034–1036. https://doi.org/10.1016/j.oret.2020.05.020
Antoszyk, Andrew N., Kathleen Wade Tarnowski, Karen Basu, Jason S. Ehrlich, and Zdenka Haskova. “Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.Ophthalmology. Retina 4, no. 10 (October 2020): 1034–36. https://doi.org/10.1016/j.oret.2020.05.020.
Antoszyk AN, Tarnowski KW, Basu K, Ehrlich JS, Haskova Z. Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema. Ophthalmology Retina. 2020 Oct;4(10):1034–6.
Antoszyk, Andrew N., et al. “Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.Ophthalmology. Retina, vol. 4, no. 10, Oct. 2020, pp. 1034–36. Epmc, doi:10.1016/j.oret.2020.05.020.
Antoszyk AN, Tarnowski KW, Basu K, Ehrlich JS, Haskova Z. Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema. Ophthalmology Retina. 2020 Oct;4(10):1034–1036.
Journal cover image

Published In

Ophthalmology. Retina

DOI

EISSN

2468-6530

ISSN

2468-7219

Publication Date

October 2020

Volume

4

Issue

10

Start / End Page

1034 / 1036

Related Subject Headings

  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Tomography, Optical Coherence
  • Ranibizumab
  • Macular Edema
  • Intravitreal Injections
  • Humans
  • Diabetic Retinopathy
  • Angiogenesis Inhibitors